口服抗凝药物在肥胖人群中的应用
Use of oral anticoagulants in obese people
刘昱杉 1丁瑞恒1
作者信息
- 1. 100038 北京市,首都医科大学附属复兴医院肾内科
- 折叠
摘要
直接口服抗凝药物(DOACs)在治疗静脉血栓栓塞症以及预防非瓣膜性心房颤动患者的缺血性脑卒中的应用越来越广泛.肥胖患者是静脉血栓栓塞和心房颤动的高风险人群,DOACs在肥胖患者的临床应用经验较少,而且其药代动力学不同于正常体重人群,本文基于现有的研究数据对此类患者应用直接口服抗凝药物进行总结,为临床医务工作者提供一定的依据.
Abstract
Direct oral anticoagulants(DOACs)are increasingly used in the treatment of venous thromboembolism and prevention of ischemic stroke in the nonvalvular atrial fibrillation patients.Obese patients are at high risk of venous thromboembolism and atrial fibrillation.DOACs had less experience in the obese patients so far and their pharmacokinetics are different from the normal.Based on the researched data,the paper summarizes the application of DOACs in obese patients,providing certain basis for clinicans.
关键词
肥胖/静脉血栓栓塞/心房颤动/直接口服抗凝药物Key words
Obesity/Thromboembolism/Atrial fibrillation/Direct oral anticoagulants引用本文复制引用
出版年
2024
NETL
NSTL
万方数据